Search Results

You are looking at 51 - 60 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

BPI24-025: Prostate Biopsies Against Medical Advice: Unveiling New Biomarker Insights for Men

Jason Alter, Sonia Kumar, Johan Skog, Vinita Verma, Kyle Schimizzi, Yiyuan Yao, Christian J. Ray, Brian Haynes, and Ronald Tutrone

– 889 . 2. McKiernan J , Donovan MJ , Margolis E , A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen

Full access

Prostate Cancer Early Detection, Version 2.2015

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Daniel A. Barocas, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenke, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah Freedman-Cass

://www.nlm.nih.gov/bsd/bsd_key.html . Accessed July 24, 2014 . 4. Catalona WJ Partin AW Slawin KM . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial . JAMA

Full access

HSR22-174: Are We ‘Choosing Wisely’? A Case of Unnecessary Staging Imaging in Older Patients With Prostate Cancer

Ami Vyas, Gavino Puggioni, and Stephen Kogut

≤6 or prostate specific antigen level of ≤10 ng/ml during 2007-2015 (N=55,705). The proportion of patients who received at least one staging imaging procedure including Positron Emission Tomography, Computerized Tomography, and radionuclide bone scans

Full access

CLO24-064: Evaluation of the Reliability of mpMRI in Diagnosing Prostate Cancer Following Intravesical Bacillus Calmette Guerin Therapy for Bladder Cancer

Arjun Pon Avudaiappan, Pushan Prabhakar, Surya Chundru, Andrew Renshaw, Ahmed Eldefrawy, Jorge Caso, and Murugesan Manoharan

120 patients who received intravesical BCG immunotherapy, 10 patients had elevated prostate-specific antigen. These patients had been further evaluated with mpMRI and MR fusion biopsy. A descriptive analysis of these patients was performed, and we

Full access

CGE22-098: Correlation Between Trough Level of Abiraterone Acetate and PSA Response in Metastatic Hormone Sensitive Prostate Cancer

Zin Myint, Jill Kolesar, Joseph R McCorkle, Jianrong Wu, Carleton S Ellis, Danielle E Otto, and Peng Wang

Background : Studies have demonstrated that in patients with metastatic hormone sensitive prostate cancer (mHSPC), a prostate-specific antigen (PSA) level at 7-months of ≤ 0.2 ng/ml is associated with a longer overall survival than a 7-month PSA

Full access

CLO22-078: Dual-Tracer PET/CT-Targeted, mpMRI-Targeted, Systematic Biopsy, and Combined Biopsy for the Diagnosis of Prostate Cancer

Dong-Xu Qiu, Jian Li, Jin-Wei Zhang, Min-Feng Chen, Xiao-Mei Gao, Yong-Xiang Tang, Ye Zhang, Xiao-Ping Yi, Hong-ling Yin, Yu Gan, Gui-Lin Wang, Xiong-Bing Zu, Shuo Hu, and Yi Cai

-TB. CLO22-078 Table 1. Baseline characteristics. * Tumor stage is reported as the clinical stage in the biopsy cohorts. IQR= interquartile range; PSA= prostate-specific antigen; mpMRI= multi-parametric magnetic resonance imaging; PSMA= prostate

Full access

CLO20-063: Late Dosing of Leuprolide and Testosterone Levels >20NG/DL in Prostate Cancer Patients

Przemyslaw Twardowski, Stuart Atkinson, Deborah M. Boldt-Houle, and Raoul S. Concepcion

prostate-specific antigen (PSA) levels on ADT may represent true disease progression to castration-resistant PCa, or may be a result of late ADT dosing and inadequate T suppression. This study evaluated the timeliness of leuprolide dosing, subsequent rate

Full access

NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023

Featured Updates to the NCCN Guidelines

Kelvin A. Moses, Preston C. Sprenkle, Clinton Bahler, Geoffrey Box, Sigrid V. Carlsson, William J. Catalona, Douglas M. Dahl, Marc Dall’Era, John W. Davis, Bettina F. Drake, Jonathan I. Epstein, Ruth B. Etzioni, Thomas A. Farrington, Isla P. Garraway, David Jarrard, Eric Kauffman, Deborah Kaye, Adam S. Kibel, Chad A. LaGrange, Paul Maroni, Lee Ponsky, Brian Reys, Simpa S. Salami, Alejandro Sanchez, Tyler M. Seibert, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Mark D. Tyson, Neha Vapiwala, Robert Wake, Samuel Washington, Alice Yu, Bertram Yuh, Ryan A. Berardi, and Deborah A. Freedman-Cass

balance between these goals: optimizing the early detection protocol, including the age at which to start and stop prostate-specific antigen (PSA) testing and the testing intervals; recommending other biomarker testing and multiparametric MRI (mpMRI

Full access

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Simon Kim, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Kelvin A. Moses, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenkle, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah A. Freedman-Cass

, while minimizing unnecessary procedures and the detection of indolent disease. Population-based prostate cancer screening studies have shown survival benefits using prostate-specific antigen (PSA) levels, sometimes in combination with a digital rectal

Full access

Early Detection and Biomarkers in Pancreatic Cancer

David E. Misek, Tasneem H. Patwa, David M. Lubman, and Diane M. Simeone

prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing . JAMA 1995 ; 274 : 1445 – 1449 . 17. Lynge E . Screening for cancer of the cervix uteri . World J Surg 1989 ; 13 : 71 – 78 . 18